Despite the remarkable advances in medicine in the past century, there are still diseases that remain frustratingly beyond the grasp of the latest drugs, devices and surgical interventions. These are not niche conditions, but issues affecting billions of people worldwide, exacerbated in many countries by ageing populations.
In the human body, Nitric Oxide (NO) is a naturally-occurring signaling molecule that is known to:
regulate blood flow (1,9-11)
modulate inflammation (1-4)
stimulate tissue regeneration (3,9), and
combat infection (4-8).
As a result, it is widely acknowledged as having huge promise as a powerful weapon in the battle against multiple diseases.
The manipulation of the body’s own Nitric Oxide’s biochemical pathways is already being leveraged by a range of drugs for diseases as diverse as heart disease and erectile dysfunction.
However, because these drugs work systemically, they open the patient to the potential consequences of systemic NO activation; in particular generalized vasodilation (46).
Our technology, IonoJet™, allows for the targeted delivery of NO, produced at the point of therapy from room air, in a vehicle, thermal plasma, which facilitates delivery of the NO to the specific tissues requiring treatment (45).
We are on a mission to leverage our patented IonoJet™ technology in the development of therapies - based on the safe, convenient and affordable delivery of NO directly to the treatment site.